X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (29) 29
index medicus (26) 26
humans (24) 24
crizotinib (22) 22
alectinib (19) 19
anaplastic lymphoma kinase (16) 16
lung neoplasms - drug therapy (14) 14
carcinoma, non-small-cell lung - drug therapy (13) 13
alk-rearranged nsclc (12) 12
crizotinib resistance (12) 12
acquired-resistance (11) 11
lung neoplasms - genetics (11) 11
receptor protein-tyrosine kinases - genetics (11) 11
mutation (10) 10
protein kinase inhibitors - therapeutic use (10) 10
cancer (9) 9
cell lung-cancer (9) 9
chemotherapy (9) 9
female (9) 9
lung cancer, non-small cell (9) 9
lung neoplasms - pathology (9) 9
open-label (9) 9
respiratory system (9) 9
adenocarcinoma (8) 8
animals (8) 8
antineoplastic agents - therapeutic use (8) 8
carcinoma, non-small-cell lung - genetics (8) 8
carcinoma, non-small-cell lung - pathology (8) 8
ceritinib (8) 8
lung cancer (8) 8
middle aged (8) 8
resistance (8) 8
inhibitor (7) 7
male (7) 7
pyrazoles - therapeutic use (7) 7
pyridines - therapeutic use (7) 7
rearranged nsclc patients (7) 7
receptor protein-tyrosine kinases - antagonists & inhibitors (7) 7
tyrosine kinase inhibitors (7) 7
alk (6) 6
confer resistance (6) 6
drug therapy (6) 6
gene rearrangement (6) 6
kinase (6) 6
non-small cell lung cancer (6) 6
nsclc (6) 6
respiratory tract diseases (6) 6
review (6) 6
adult (5) 5
antineoplastic agents - pharmacology (5) 5
carbazoles - therapeutic use (5) 5
carcinoma, non-small-cell lung - enzymology (5) 5
drug resistance (5) 5
drug resistance, neoplasm - genetics (5) 5
gene (5) 5
immunohistochemistry (5) 5
inhibitors (5) 5
lung neoplasms - enzymology (5) 5
lymphoma (5) 5
mutations (5) 5
piperidines - therapeutic use (5) 5
protein kinase inhibitors - pharmacology (5) 5
research (5) 5
aged (4) 4
alk-rearranged adenocarcinoma (4) 4
article (4) 4
biopsy (4) 4
drug resistance, neoplasm (4) 4
eml4-alk (4) 4
epidermal growth factor (4) 4
fusion (4) 4
genetic aspects (4) 4
hemic and lymphatic diseases (4) 4
identification (4) 4
kinases (4) 4
lung-cancer (4) 4
metastasis (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
non-small cell lung carcinoma (4) 4
non-small-cell lung cancer (4) 4
pharmacology & pharmacy (4) 4
phase-ii trial (4) 4
rearranged during transfection (4) 4
receptor protein-tyrosine kinases - metabolism (4) 4
targeted therapies (4) 4
targeted therapy (4) 4
tumors (4) 4
tyrosine (4) 4
1st-line treatment (3) 3
activating mutations (3) 3
adenocarcinoma - genetics (3) 3
alk inhibitors (3) 3
antitumor-activity (3) 3
carcinoma, non-small-cell lung - metabolism (3) 3
cell biology (3) 3
ch5424802 (3) 3
clinical-response (3) 3
development and progression (3) 3
disease progression (3) 3
egfr (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2014, Volume 9, Issue 12, pp. 1821 - 1825
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 09/2018, Volume 123, pp. 83 - 86
Acquired secondary mutations in the anaplastic lymphoma kinase ( ) gene have been identified in -rearranged non–small cell lung cancer (NSCLC) patients who are... 
ALK G1128A | Next-generation sequencing | ALK-rearranged NSCLC | Crizotinib resistance | LUNG-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | ALECTINIB | KINASE | Genetic aspects | Lymphomas | Drug resistance | Lung cancer, Non-small cell | Analysis
Journal Article
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, ISSN 1084-9521, 04/2017, Volume 64, pp. 150 - 157
Patients are diagnosed as anaplastic lymphoma kinase (ALK) positive, i.e. exhibiting the ALK rearrangement, and comprise 3-7% of non-small-cell lung cancer... 
ALK | Crizotinib | EML4-ALK FUSION | KINASE | F1174V MUTATION | REARRANGED NSCLC PATIENTS | DEVELOPMENTAL BIOLOGY | ANTITUMOR-ACTIVITY | CELL BIOLOGY | Alectinib | Lorlatinib | CLINICAL INFORMATICS | Point mutation | INTEGRATING INFLAMMATORY MEDIATORS | LUNG-CANCER NSCLC | INHIBITOR | Ceritinib
Journal Article
ONCOTARGET, 03/2015, Volume 6, Issue 8, pp. 5720 - 5734
ALK is involved in the onset of several tumors. Crizotinib (Xalkori (TM)), a potent ALK inhibitor, represents the current front-line treatment for ALK+ NSCLC... 
NPM/ALK | TYROSINE KINASE | ASP3026 | CH5424802 | REARRANGED NSCLC PATIENTS | IDENTIFICATION | resistance | PF-06463922 | CONFER RESISTANCE | CELL BIOLOGY | ANAPLASTIC LYMPHOMA KINASE | LUNG-CANCER | inhibitor | CERITINIB | CRIZOTINIB RESISTANCE | ACTIVATING MUTATIONS
Journal Article
Annual Review of Cancer Biology, ISSN 2472-3428, 3/2017, Volume 1, Issue 1, pp. 257 - 274
Advances in genomics, an improved understanding of malignant transformation, and the development of potent small molecule inhibitors capable of targeting key... 
tyrosine kinase inhibitors | drug resistance | targeted therapies | non-small-cell lung cancer | 1ST-LINE TREATMENT | ACQUIRED-RESISTANCE | REARRANGED NSCLC PATIENTS | EGFR MUTATION | CONFER RESISTANCE | ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | CRIZOTINIB RESISTANCE | GASTROINTESTINAL STROMAL TUMORS | CLINICAL-RESPONSE | IMATINIB MESYLATE
Journal Article
Journal Article
2017, Annual Review of Cancer Biology-Series, Volume 1, 18
Advances in genomics, an improved understanding of malignant transformation, and the development of potent small molecule inhibitors capable of targeting key... 
1ST-LINE TREATMENT | targeted therapies | ACQUIRED-RESISTANCE | REARRANGED NSCLC PATIENTS | EGFR MUTATION | CONFER RESISTANCE | tyrosine kinase inhibitors | ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | CRIZOTINIB RESISTANCE | drug resistance | GASTROINTESTINAL STROMAL TUMORS | CLINICAL-RESPONSE | IMATINIB MESYLATE | non-small-cell lung cancer
Book Chapter
Cancer Biology & Therapy, ISSN 1538-4047, 11/2018, Volume 19, Issue 11, pp. 962 - 966
The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than... 
fusion partner gene | crizotinib | CMTR1 | ALK-tyrosine kinase inhibitor (TKI) | ALK-rearranged NSCLC | Anaplastic lymphoma kinase (ALK) | VARIANT | CHEMOTHERAPY | LUNG-CANCER | GENE | ONCOLOGY | KIF5B-ALK | CANCER STATISTICS
Journal Article